title: Ehrlich ascites tumor as a tool in the development of compounds with immunomodulatory properties.
abstract: In previous works, we have demonstrated that the myeloprotective properties of several natural and synthetic compounds are partly responsible for their antitumor activity in the Ehrlich ascites tumor (EAT) model. In this work, we present information that may be useful to the study of pharmacological and toxicological properties of compounds that affect the hematological compartment. Clonogenic studies in EAT-inoculated mice demonstrated a rapid decrease in bone marrow CFU-GM, whereas a progressive increase in splenic CFU-GM and cellularity was observed, followed by splenomegaly. Bone marrow cellularity declined on the third day after tumor challenge, returning to normal values thereafter. Serum from EAT-bearing mice produced detectable colony-stimulating activity in vitro. Similar results were observed with the conditioned medium from Ehrlich tumor cell cultures, but not with the cell-free Ehrlich tumor ascitic fluid. Tumor inoculation also resulted in a more striking depletion in the number of non-adherent cells in long-term bone marrow cell cultures (LTBMCs) with no bone marrow stroma formation. We speculate that the physiological alterations induced by the EAT growth can be used to assess the ability of compounds to modulate the hematopoietic response.
authors.affiliation: Departamento de Farmacologia/Hemocentro, Faculdade de Ciências Médicas, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil. mlsq@fcm.unicamp.br
authors.forename: Mary L S
authors.initials: ML
authors.lastname: Queiroz
authors.forename: M C
authors.initials: MC
authors.lastname: Valadares
authors.forename: C
authors.initials: C
authors.lastname: Bincoletto
authors.forename: G C
authors.initials: GC
authors.lastname: Dieamant
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001202:Ascitic Fluid / Q000473:pathology; D001854:Bone Marrow Cells / Q000276:immunology / Q000473:pathology; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D002452:Cell Count; D045744:Cell Line, Tumor; D003114:Colony-Forming Units Assay; D015195:Drug Design; D006410:Hematopoiesis / Q000187:drug effects* / Q000276:immunology; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000276:immunology; D007155:Immunologic Factors / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D013154:Spleen / Q000276:immunology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors